Table 4. Five-year actuarial recurrence rates for 461 stage II endometrial cancer patients.
| Variables | All stage II | LN resection | Postoperative radiotherapy | |||
|---|---|---|---|---|---|---|
| No LN resection | LN resection | No radiotherapy | EBRT | |||
| Number | 461 | 248 | 213 | 344 | 117 | |
| a) Total recurrence rate | 105 (23.6) | 57 (24.1) | 48 (23.2)† | 84 (25.6) | 21 (18.2)† | |
| All vaginal | 53 (12.4) | 30 (12.9) | 23 (11.8)† | 45 (14.2) | 8 (7.3)† | |
| All pelvic | 41 (10.1) | 20 (9.3) | 21 (11.0) | 38 (12.7) | 3 (2.8)† | |
| All abdominal | 37 (9.1) | 22 (10.1) | 15 (7.9) | 27 (9.2) | 10 (8.9) | |
| All distant | 45 (11.2) | 22 (10.7) | 23 (11.9) | 33 (11.4) | 12 (11.0) | |
| b) Site of most severe 1. recurrence | ||||||
| Vaginal | 26 (6.2) | 16 (6.9) | 10 (5.4)† | 23 (7.4) | 3 (2.8)† | |
| Pelvic | 14 (3.6) | 7 (3.5) | 7 (3.8) | 13 (4.5) | 1 (1.1) | |
| Abdominal | 19 (4.6) | 12 (5.4) | 7 (3.8) | 14 (4.7) | 5 (4.5) | |
| Distant | 45 (11.2) | 22 (10.7) | 23 (11.9) | 33 (11.4) | 12 (11.0) | |
| c) Locoregional LN recurrences | 40 (9.9) | 21 (9.9) | 19 (10.0) | 32 (10.9) | 8 (7.4) | |
| All PL | 29 (7.3) | 14 (6.5) | 15 (8.1) | 27 (9.4) | 2 (1.8) | |
| All PA | 22 (5.5) | 16 (7.7) | 6 (3.1)† | 14 (4.8) | 8 (7.4) | |
| d) Extra abdominal LN | 10 (2.5) | 6 (3.0) | 4 (2.1) | 8 (2.8) | 2 (1.8) | |
Values are presented as number (%).
Recurrences were divided into 1. Given or not given RT 2. LN resected or not. Recurrences divided into a) Total recurrence rate: number of recurrences at each location: vaginal, pelvic, abdominal, or distant metastasis. If a patient had recurrences at several sites, the patient can be represented more than once, b) First recurrence: most serious first recurrence in order of distant>abdominal>pelvic>vaginal, c) Locoregional LN recurrences (pelvic or aortic LN), and d) Extra abdominal LN (inguinal, mediastinal, neck, and axillar).
aHR, adjusted hazard ratio; EBRT, external beam radiotherapy; HR, hazard ratio; LN, lymph node; PA, paraaortic lymph nodes; PL, pelvic lymph nodes.
†p <0.05 using aHR: HR/aHR: adjusted for significant or potential confounders by multivariate analysis including age, American Society of Anesthesiologists, grades 1, 2, 3, unfavorable tumor types, type of hysterectomy, LN resection, adjuvant EBRT, or chemotherapy.